The trial is investigating the efficacy of alectinib in patients with advanced stage
RET-rearranged NSCLC, treated with at least one platinum based systemic chemotherapy regimen.
Preclinical studies have shown that alectinib, a highly selective next generation ALK
inhibitor, has potent anti-tumour activity in RET-rearranged NSCLC. Therapeutically, several
multiple kinases inhibitors, are potentially able to inhibit RET kinase function, which has
been tested in several unselected NCSLC trials. However, those result were negative and none
of the tested drugs was approved for lung cancer treatment.
The ALERT-lung trial is a single arm, phase II trial with the primary objective to assess the
efficacy of alectinib in terms of best overall response (OR) assessed by RECIST v1.1 in
selected NSCLC patients with RET rearrangement. The secondary objectives are to evaluate
secondary measures of clinical efficacy including disease control, progression-free survival
(PFS), and overall survival (OS) as well as to assess safety and tolerability of the
treatment and to describe the association of primary and secondary outcomes with tumour
characteristics.
Alectinib is administered orally, 600 mg, twice per day, until progression, refusal or
unacceptable toxicity. Trial treatment may also continue beyond progression, with physician
and patient agreement, for as long as the patient may still derive clinical benefit. A total
sample size of 44 patients is required.
Inclusion Criteria:
1. Histologically or cytologically documented non-small cell lung carcinoma
2. Advanced disease defined as recurrent stage IV (according to 8th TNM classification)
or recurrent or progressive disease following multimodal therapy (radiation therapy,
surgical resection, or definitive chemo-radiation therapy for locally advanced
disease)
3. At least one prior platinum-based systemic regimen: Adjuvant or neoadjuvant or
definitive platinum-based chemo-radiotherapy treatments are considered as a line of
treatment only if completed less than 6 months before enrolment. Maintenance therapy
following platinum doublet-based chemotherapy is not considered a separate regimen of
therapy.
4. RET rearrangement detected by FISH, Nanostring or by parallel-sequencing on FFPE
tumour tissue assessed locally.
5. Availability of FFPE tumour material for central confirmation of RETrearrangement
6. Measurable or non-measurable, but radiologically evaluable (except for skin lesions)
disease according to RECIST v1.1 criteria
7. Age ≥18 years
8. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
9. Life expectancy >3 months
10. Adequate haematological function:
- Haemoglobin ≥9 g/dL
- Neutrophil count ≥1.5 ×109/L
- Platelet count ≥100 × 109/L
- WBC ≥2 ×109/L
11. Adequate renal function: Calculated creatinine clearance ≥45 mL/min (according to
Cockcroft-Gault formula)
12. Adequate liver function:
- Total bilirubin ≤2x ULN (except patients with Gilbert Syndrome, who can have
total bilirubin ≤3.0 mg/dL)
- ALT and AST ≤3x ULN (≤5x ULN for patients with concurrent liver ¨ metastasis)
13. Patient capable of proper therapeutic compliance, and accessible to correct followup.
14. Women of childbearing potential, including women who had their last menstrual period
in the last 2 years, must have a negative serum or urine beta HCG pregnancy test
within 7 days before enrolment into the trial and within 3 days before alectinib
treatment start.
15. Sexually active men and women of childbearing potential must use an effective
contraceptive method (intrauterine devices without hormones, bilateral tubal
occlusion, vasectomized partner or total abstinence) during the trial treatment and
for a period of at least 3 months following the last dose of alectinib.
16. Recovered from any previous therapy related toxicity to Grade ≤1 at date of enrolment
(except for recovery to Grade ≤2 of alopecia, fatigue, creatinine increased, lack of
appetite or peripheral neuropathy)
17. Written Informed Consent (IC) for trial treatment must be signed and dated by the
patient and the investigator prior to any trial-related intervention.
Exclusion Criteria:
1. Untreated, active CNS metastases
2. Carcinomatous meningitis
3. Any previous (in the past 3 years) or concomitant malignancy EXCEPT adequately treated
basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or
bladder, in situ ductal carcinoma of the breast
4. Any serious diseases or clinical conditions, including but not limited to uncontrolled
active infection and any other serious underlying medical processes, that could affect
the patient's capacity to participate in the trial
5. Liver disease characterized by:
- ALT or AST >3 × ULN (>5 × ULN for patients with concurrent liver metastasis)
confirmed on two consecutive measurements or
- Impaired excretory function (e.g., hyperbilirubinaemia) or synthetic function or
other conditions of decompensated liver disease such as coagulopathy, hepatic
encephalopathy, hypoalbuminaemia, ascites, and bleeding from oesophageal varices
or
- Acute viral or active autoimmune, alcoholic, or other types of acute hepatitis
6. Patients with baseline symptomatic bradycardia
7. Previous treatment with any RET TKI or RET targeted therapy.
8. Known EGFR, ALK, ROS, and BRAF mutation (in addition to RET rearrangement)
9. Any concurrent systemic anticancer therapy.
10. Any GI disorder that may affect absorption of oral medications, such as malabsorption
syndrome or status post major bowel resection.
11. History of hypersensitivity to any of the additives in the alectinib drug formulation.
12. Known HIV positivity or AIDS-related illness.
13. Women who are pregnant or in the period of lactation.
